
Health Equity & Access Weekly Roundup: June 22, 2024
This week, the Center on Health Equity & Access featured expert perspectives on sickle cell disease, obesity, psychological safety, LGBTQ+ health, and postpartum depression.
This episode of
In honor of World Sickle Cell Day, this feature article reviewed the milestone moments for the community from the last year. At the end of 2023, the FDA approved 2 innovative gene therapies, exa-cel and lovo-cel, offering potential cures for
Zuranolone (Zurzuvae) has revolutionized postpartum depression (PPD) treatment by offering the first oral medication that can be taken at home. Unlike the older intravenous infusion brexanolone, which requires hospital monitoring, zuranolone provides rapid relief without separating mothers from their babies. Rachel Dalthorp, MD, explained that this neurosteroid significantly improves care for mothers, allowing them to manage PPD effectively and conveniently at home.
In an article authored by Carolyn Tandy, senior vice president and chief diversity, equity, and inclusion officer of Humana, she addressed the increasing burnout and resignations among US workers and how it's impacted patient care and public health. Psychological safety, where employees feel safe to speak up and be themselves without fear, is essential. Most employees prioritize workplaces that value their well-being, according to a recent survey highlighted. Tandy emphasized that leaders must promote a safe, inclusive workplace to empower staff and enhance patient care.
At a recent
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.